×
Hero Background

Pseudomonas Aeruginosa Treatment Companies

ID: MRFR/HC/6966-HCR
105 Pages
Rahul Gotadki
October 2025

Pseudomonas aeruginosa is a bacterial pathogen that can cause infections, particularly in individuals with weakened immune systems or underlying health conditions. Treatment of Pseudomonas aeruginosa infections typically involves antibiotics, and various pharmaceutical companies have developed drugs targeting this bacterium.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Pseudomonas Aeruginosa Treatment Market Research Report - Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Pseudomonas Aeruginosa Treatment Market

Pseudomonas Aeruginosa Treatment Key CompaniesLatest Pseudomonas Aeruginosa Treatment Companies Update

Nov 2023: Kite, a Gilead Company, and Arcellx, Inc. announced that they have extended their current partnership, which was first disclosed in December 2022. In multiple myeloma, Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, which consists of SparX proteins that target BCMA and ARC-T cells. The firms have also extended their collaboration to cover lymphomas concerning Arcellx's CART-ddBCMA.   The deep and long-lasting responses seen in our CART-ddBCMA Phase 1 trial for multiple myeloma suggest that our unique synthetic binder, the D-Domain, can potentially open new avenues for developing CAR T treatments. They are eager to strengthen their partnership with Kite and increase their investment in our business as they exercise their rights under our ACLX-001 ARC-SparX program for multiple myeloma and continue making investments in our platform.


Nov 2023: Bristol-Myers Squibb bought lung cancer medication as part of its $4.1 billion acquisition of Turning Point Therapeutics last year and has received FDA approval. The medication, marketed under the brand name Augtyro, will face competition in the congested lung cancer treatment market from rival pharmaceutical companies Roche, Merck, and AstraZeneca and Opdivo, another cancer treatment from Bristol Myers.


List of Pseudomonas Aeruginosa Treatment Key companies in the market

  • Gilead Sciences Inc. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Novartis AG (Switzerland)

  • Pfizer inc. (UK)

  • Lupin Pharmaceuticals Inc. (US)

  • PARI Medical Holding GmbH (Germany)

  • AstraZeneca (UK)

  • Humanigen Inc (US)

  • Merck & Co Inc. (US)

  • AmpliPhi Biosciences Corp (US)